For research use only. Not for therapeutic Use.
CCR8 antagonist 2 is a potent antagonist of CCR8. CCR8 (C-C Motif Chemokine Receptor 8) is predominantly expressed on Treg cells and Th2 cells, but not on Th1 cells. CCR8 antagonist 2 inhibits CCR8 activity, which may be used in the research of diseases mediated by CCR8, such as cancer, and/or neuropathic pain (extracted from patent WO2022000443A1, compound 220)[1].
| Catalog Number | I043896 |
| CAS Number | 2756350-98-6 |
| Synonyms | N-[2-chloro-6-methyl-4-[[(1R)-1-(1-methylpiperidin-4-yl)ethyl]sulfamoyl]phenyl]-2-methylbenzamide |
| Molecular Formula | C23H30ClN3O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C23H30ClN3O3S/c1-15-7-5-6-8-20(15)23(28)25-22-16(2)13-19(14-21(22)24)31(29,30)26-17(3)18-9-11-27(4)12-10-18/h5-8,13-14,17-18,26H,9-12H2,1-4H3,(H,25,28)/t17-/m1/s1 |
| InChIKey | ZEDJVOTUUKLHRW-QGZVFWFLSA-N |
| SMILES | CC1=CC=CC=C1C(=O)NC2=C(C=C(C=C2C)S(=O)(=O)NC(C)C3CCN(CC3)C)Cl |
| Reference | [1]. Guohuang FAN, et al. Methods and compositions for targeting tregs using ccr8 inhibitors. |
